Tag: VIVA 2022

New study comparing DCBs to bare metal stents in femoropopliteal lesions...

 During a late-breaking clinical trials session at the 2022 Vascular Interventional Advances (VIVA) conference (31 October–3 November, Las Vegas, USA), Mehdi Shishehbor (University Hospitals...

Endologix reports five-year data of the LEOPARD trial for the treatment...

Christopher Kwolek (Massachusetts General Hospital and Harvard Medical School, Boston, USA) presented five-year results from the LEOPARD randomised controlled trial (RCT) during a late-breaking...
Disrupt

Disrupt PAD III observational study results confirm safety and effectiveness of...

The final 1,373-patient cohort analysis from the Disrupt PAD III observational study (OS) demonstrates consistent intravascular lithotripsy (IVL; Shockwave Medical) outcomes in complex and...
SurVeil

SurVeil DCB demonstrates sustained durability of safety, efficacy endpoints in TRANSCEND

In the TRANSCEND clinical trial, the SurVeil drug-coated balloon (DCB; Surmodics) demonstrated "excellent efficacy and safety" out to 24-month follow-up. This is according to...
DCBs

New analysis: Four multicentre trials support primary use of DCBs over...

A patient-level, propensity-adjusted comparison of three-year results from a quartet of prospective, multicentre trials support the primary use of drug-coated balloons (DCBs) versus bare...
BioMimics

“Excellent” three-year results presented for the BioMimics 3D stent in longer...

At the 2022 Vascular Interventional Advances (VIVA) meeting (31 October–3 November, Las Vegas, USA), Michael Lichtenberg (Arnsberg Clinic, Arnsberg, Germany) reported a subgroup analysis...